For Healthcare Professionals Outside the US
Tafinlar + Mekinist is the first and only approved targeted treatment for patients with BRAF V600+ NSCLC2
A retrospective study to investigate the prevalence, distribution, and prognostic role of BRAF mutations in a large cohort of Caucasian patients with NSCLC (N=1046).1
References: 1. Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non–small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29(26):3574-3579.
2. Tafinlar Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2017.